Concepts (152)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pregnancy Complications, Infectious | 7 | 2022 | 507 | 0.650 |
Why?
|
| Antibodies, Viral | 6 | 2021 | 266 | 0.630 |
Why?
|
| Influenza Vaccines | 5 | 2020 | 132 | 0.600 |
Why?
|
| Antibodies, Bacterial | 4 | 2023 | 149 | 0.540 |
Why?
|
| Infant, Newborn | 11 | 2023 | 1410 | 0.530 |
Why?
|
| Pneumococcal Vaccines | 3 | 2014 | 252 | 0.520 |
Why?
|
| Influenza, Human | 5 | 2020 | 360 | 0.510 |
Why?
|
| Pneumococcal Infections | 3 | 2014 | 287 | 0.500 |
Why?
|
| HIV Infections | 12 | 2022 | 4946 | 0.470 |
Why?
|
| Immunoglobulin G | 5 | 2023 | 220 | 0.450 |
Why?
|
| Antibody Formation | 2 | 2013 | 61 | 0.450 |
Why?
|
| Female | 24 | 2023 | 8751 | 0.450 |
Why?
|
| Infectious Disease Transmission, Vertical | 5 | 2022 | 467 | 0.420 |
Why?
|
| Humans | 28 | 2023 | 14077 | 0.410 |
Why?
|
| Infant | 15 | 2023 | 2145 | 0.400 |
Why?
|
| Premature Birth | 2 | 2022 | 76 | 0.380 |
Why?
|
| Streptococcal Infections | 2 | 2023 | 179 | 0.350 |
Why?
|
| Pregnancy | 12 | 2023 | 1815 | 0.330 |
Why?
|
| Male | 16 | 2022 | 6489 | 0.290 |
Why?
|
| South Africa | 15 | 2022 | 7312 | 0.260 |
Why?
|
| HIV | 2 | 2006 | 380 | 0.260 |
Why?
|
| Preventive Health Services | 1 | 2005 | 17 | 0.250 |
Why?
|
| Body Fluids | 1 | 2005 | 5 | 0.250 |
Why?
|
| AIDS Serodiagnosis | 1 | 2005 | 44 | 0.240 |
Why?
|
| Streptococcus agalactiae | 2 | 2023 | 197 | 0.230 |
Why?
|
| Adult | 11 | 2021 | 5664 | 0.220 |
Why?
|
| Magnetoencephalography | 2 | 2021 | 3 | 0.220 |
Why?
|
| Streptococcal Vaccines | 1 | 2023 | 45 | 0.210 |
Why?
|
| School Health Services | 1 | 2003 | 19 | 0.210 |
Why?
|
| Chorioamnionitis | 1 | 2022 | 10 | 0.210 |
Why?
|
| Morbidity | 1 | 2022 | 37 | 0.200 |
Why?
|
| Violence | 1 | 2003 | 68 | 0.200 |
Why?
|
| Maternal Mortality | 1 | 2022 | 54 | 0.200 |
Why?
|
| Infant Mortality | 1 | 2022 | 92 | 0.190 |
Why?
|
| Beta Rhythm | 1 | 2021 | 1 | 0.190 |
Why?
|
| Motor Cortex | 1 | 2021 | 2 | 0.190 |
Why?
|
| Dried Blood Spot Testing | 1 | 2021 | 22 | 0.190 |
Why?
|
| Young Adult | 8 | 2021 | 2357 | 0.190 |
Why?
|
| Longitudinal Studies | 4 | 2022 | 409 | 0.190 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 84 | 0.190 |
Why?
|
| Rubella | 1 | 2019 | 5 | 0.170 |
Why?
|
| Rubella virus | 1 | 2019 | 8 | 0.170 |
Why?
|
| Cytomegalovirus Infections | 1 | 2019 | 23 | 0.170 |
Why?
|
| Immunization, Secondary | 2 | 2011 | 62 | 0.160 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2019 | 73 | 0.160 |
Why?
|
| Streptococcus pneumoniae | 2 | 2014 | 320 | 0.160 |
Why?
|
| Prospective Studies | 4 | 2019 | 1131 | 0.150 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2016 | 18 | 0.140 |
Why?
|
| Disease Transmission, Infectious | 1 | 2015 | 39 | 0.130 |
Why?
|
| Time Factors | 2 | 2014 | 503 | 0.120 |
Why?
|
| Visual Perception | 1 | 2014 | 1 | 0.120 |
Why?
|
| Feedback, Sensory | 1 | 2014 | 1 | 0.120 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 112 | 0.120 |
Why?
|
| Cerebral Cortex | 1 | 2014 | 9 | 0.120 |
Why?
|
| Proteolysis | 1 | 2014 | 2 | 0.120 |
Why?
|
| Membrane Glycoproteins | 1 | 2014 | 11 | 0.120 |
Why?
|
| Neoplasm Proteins | 1 | 2014 | 9 | 0.120 |
Why?
|
| Double-Blind Method | 4 | 2020 | 263 | 0.120 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2014 | 10 | 0.120 |
Why?
|
| Lectins | 1 | 2014 | 8 | 0.120 |
Why?
|
| Vaccines | 1 | 2015 | 84 | 0.110 |
Why?
|
| Carrier State | 1 | 2014 | 89 | 0.110 |
Why?
|
| Milk, Human | 1 | 2014 | 22 | 0.110 |
Why?
|
| Pregnancy Outcome | 3 | 2022 | 112 | 0.110 |
Why?
|
| Rotavirus Infections | 1 | 2014 | 46 | 0.110 |
Why?
|
| Rotavirus Vaccines | 1 | 2014 | 53 | 0.110 |
Why?
|
| Breast Feeding | 1 | 2014 | 119 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 3 | 2016 | 260 | 0.110 |
Why?
|
| Adolescent | 4 | 2020 | 2858 | 0.100 |
Why?
|
| Age Factors | 1 | 2013 | 364 | 0.100 |
Why?
|
| Poliovirus Vaccine, Inactivated | 1 | 2011 | 17 | 0.100 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2011 | 28 | 0.100 |
Why?
|
| Haemophilus Vaccines | 1 | 2011 | 38 | 0.100 |
Why?
|
| Seroepidemiologic Studies | 2 | 2023 | 104 | 0.090 |
Why?
|
| Vaccines, Inactivated | 3 | 2016 | 23 | 0.090 |
Why?
|
| Developing Countries | 3 | 2015 | 385 | 0.090 |
Why?
|
| Retrospective Studies | 1 | 2013 | 767 | 0.090 |
Why?
|
| Cohort Studies | 3 | 2015 | 939 | 0.090 |
Why?
|
| Placenta | 2 | 2022 | 43 | 0.080 |
Why?
|
| Pregnant Women | 2 | 2020 | 89 | 0.080 |
Why?
|
| Immunity, Maternally-Acquired | 2 | 2023 | 40 | 0.080 |
Why?
|
| Vaccines, Combined | 2 | 2023 | 34 | 0.080 |
Why?
|
| Child | 3 | 2022 | 2180 | 0.080 |
Why?
|
| Child, Preschool | 3 | 2014 | 1675 | 0.080 |
Why?
|
| Risk Factors | 2 | 2019 | 1431 | 0.080 |
Why?
|
| DNA, Viral | 2 | 2005 | 165 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2005 | 380 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2019 | 150 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 1377 | 0.070 |
Why?
|
| Vaccines, Conjugate | 2 | 2023 | 161 | 0.070 |
Why?
|
| Hemagglutination Inhibition Tests | 2 | 2016 | 23 | 0.060 |
Why?
|
| Immunization Schedule | 2 | 2020 | 70 | 0.060 |
Why?
|
| Infant Care | 1 | 2005 | 10 | 0.060 |
Why?
|
| Diagnosis, Oral | 1 | 2005 | 2 | 0.060 |
Why?
|
| Medically Underserved Area | 1 | 2005 | 13 | 0.060 |
Why?
|
| Sex Distribution | 1 | 2005 | 89 | 0.060 |
Why?
|
| Age Distribution | 1 | 2005 | 106 | 0.060 |
Why?
|
| Health Care Costs | 1 | 2005 | 107 | 0.060 |
Why?
|
| Cost of Illness | 1 | 2005 | 155 | 0.060 |
Why?
|
| Health Personnel | 1 | 2005 | 229 | 0.050 |
Why?
|
| Surveys and Questionnaires | 1 | 2005 | 532 | 0.050 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2005 | 235 | 0.050 |
Why?
|
| Models, Psychological | 1 | 2003 | 2 | 0.050 |
Why?
|
| Health Services Accessibility | 1 | 2005 | 265 | 0.050 |
Why?
|
| Incidence | 1 | 2005 | 655 | 0.050 |
Why?
|
| Demography | 1 | 2003 | 105 | 0.050 |
Why?
|
| HIV Seropositivity | 1 | 2005 | 263 | 0.050 |
Why?
|
| Birth Weight | 1 | 2022 | 78 | 0.050 |
Why?
|
| Movement | 1 | 2021 | 5 | 0.050 |
Why?
|
| Psychomotor Performance | 1 | 2021 | 12 | 0.050 |
Why?
|
| Child Health | 1 | 2022 | 76 | 0.050 |
Why?
|
| Schools | 1 | 2022 | 67 | 0.050 |
Why?
|
| Risk Reduction Behavior | 1 | 2021 | 39 | 0.050 |
Why?
|
| Serogroup | 1 | 2021 | 134 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2021 | 464 | 0.040 |
Why?
|
| Cytomegalovirus | 1 | 2019 | 24 | 0.040 |
Why?
|
| Saliva | 1 | 2019 | 22 | 0.040 |
Why?
|
| Pandemics | 1 | 2022 | 280 | 0.040 |
Why?
|
| Immunization | 1 | 2020 | 63 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2016 | 867 | 0.040 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2020 | 91 | 0.040 |
Why?
|
| HIV-1 | 1 | 2005 | 1239 | 0.040 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2016 | 13 | 0.030 |
Why?
|
| Placebos | 1 | 2016 | 44 | 0.030 |
Why?
|
| Prevalence | 1 | 2019 | 1149 | 0.030 |
Why?
|
| Temporal Lobe | 1 | 2014 | 1 | 0.030 |
Why?
|
| Brain Mapping | 1 | 2014 | 2 | 0.030 |
Why?
|
| Electroencephalography | 1 | 2014 | 9 | 0.030 |
Why?
|
| Serotyping | 1 | 2014 | 63 | 0.030 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 1 | 2014 | 42 | 0.030 |
Why?
|
| Lysosomes | 1 | 2014 | 1 | 0.030 |
Why?
|
| Endoplasmic Reticulum-Associated Degradation | 1 | 2014 | 1 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 2014 | 8 | 0.030 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2014 | 13 | 0.030 |
Why?
|
| Glycosylation | 1 | 2014 | 17 | 0.030 |
Why?
|
| Infant, Premature | 1 | 2014 | 52 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 103 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2014 | 37 | 0.030 |
Why?
|
| Kinetics | 1 | 2014 | 65 | 0.030 |
Why?
|
| Protein Binding | 1 | 2014 | 62 | 0.030 |
Why?
|
| Poverty | 2 | 2005 | 149 | 0.030 |
Why?
|
| Immunogenetic Phenomena | 1 | 2014 | 7 | 0.030 |
Why?
|
| Vaccines, Attenuated | 1 | 2014 | 27 | 0.030 |
Why?
|
| Nasopharynx | 1 | 2014 | 148 | 0.030 |
Why?
|
| Gastroenteritis | 1 | 2014 | 22 | 0.030 |
Why?
|
| Immunoglobulin A | 1 | 2014 | 39 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2014 | 113 | 0.030 |
Why?
|
| Rotavirus | 1 | 2014 | 29 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2005 | 183 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2005 | 210 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2005 | 186 | 0.010 |
Why?
|
| Mothers | 1 | 2005 | 190 | 0.010 |
Why?
|